Publications by authors named "Lena Feber"
Article Synopsis
- Cognitive deficits significantly impact individuals with schizophrenia spectrum disorders (SSDs), and while antipsychotics are commonly used, they don’t enhance cognition and vary in their effectiveness based on their receptor profiles.
- The study aimed to assess the relationship between various antipsychotic treatments and cognitive performance in SSD patients by analyzing numerous randomized clinical trials.
- Findings showed that while no specific antipsychotic consistently performed better than placebo in improving cognition, collectively, antipsychotics had a small positive effect on cognitive outcomes compared to no treatment.
Introduction: Treating the early phase of schizophrenia is crucial for preventing further episodes and improving quality of life, functioning, and social inclusion. Pharmacotherapies are first-line treatments, but have limitations. There is consensus on the need for non-pharmacological interventions for individuals in the early phase of schizophrenia.
View Article and Find Full Text PDFBackground: There is evidence that antipsychotic drugs differ in their effect on the cognitive symptoms of schizophrenia. So far, there is no comprehensive systematic review available that would enable providers and patients to make informed choices regarding this important aspect of treatment. With a large number of substances available, conventional pairwise meta-analyses will not be sufficient to inform this choice.
View Article and Find Full Text PDF